New Graft Probes Cast Shadow Over China's Drug Pricing, Reimbursement Systems
'Constant Improvement' Needed
While new legislation has pushed prescription drug pricing high up the political agenda for US lawmakers, the issue has also come into the spotlight again for Chinese regulators, which have just launched new investigations into two officials. While the two countries are taking drastically different routes to tackling pricing, the developments show compliance risks remain high in China.
You may also be interested in...
A rare disclosure by China’s national health insurance payer shows how a major state-owned drug maker used its market-dominating position to dodge price-lowering schemes and increase drug prices more than 10-fold.
Latest national medical insurance negotiations results show orphan drugs are covered, but Biogen’s Spinraza gets a 95% price cut. Getting coverage, rather holding out for a high price, really makes more sense in the emerging Chinese market for rare disease drugs, industry observers say.
On a quiet May Day holiday in China, a U.S. admission scandal involving a local high-flying pharma executive hits home hard.